维普期刊资源整合服务平台（V6.5）

21篇 您的检索式：作者名="HUDES GR"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Targeting mTOR in renal cell carcinoma显示文摘	Hudes GR	2009	Cancer2009，115，10：	1
2	Targeting roTOR in renal cell carcinoma显示文摘	Hudes GR	2009	Can- er2009，115，10：	1
3	Phase I/II tri- al of temsirolimus combined with interferon alfa for advanced renal cell carcinoma显示文摘	Motzer RJ Hudes GR Curti BD	2007	J Clin Oncol2007，25，25：	1
4	Phase Ⅰ / Ⅱ trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma 显示文摘	Motzer RJ Hudes GR Curti BD	2007	J Clin Oncol2007，25，25：	1
5	Investigation of novel circulating proteins, germ linesingle-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma显示文摘	MOTZERRJ HUTSON TE HUDES GR	2014	Cancer Chemother Pharmaco12014，74，4：	1
6	Sequential axi- tinib (AG-013736) therapy of patients (pts) with metastatie clear cell renal cell eaneer (RCC) refractory to sunitinib and sorafenib, eytokines and sorafenib, or sorafenib alone 显示文摘	DUTCHER JP WILDING G HUDES GR	2008	J Clin Oneol2008，26，15：	1
7	Phase III trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma 显示文摘	Motzer RJ Hudes GR Curti BD	2007	J Clin Oncol2007，25，25：	1
8	Phase Ⅱ study of topotecan in metastic hormone refractory prostate cancer显示文摘	HUDES GR KOSIEROWSKI R GREENBERG R	1995	Invest New Drugs1995，13，3：	1
9	Serum amino acid levels as a biomarker for renal cell carcinoma 显示文摘	MUSTAFA A GUPTA S HUDES GR	2011	J Urol2011，186，4：	1
10	Phase Ⅱ trial of 96hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer 显示文摘	Nathan F Khater C	1997	J Clin Oncol1997，15，：	1
11	Targeting mTOR in renal cell carcinoma显示文摘	Hudes GR	2009	Cancer2009，115，：	1
12	Phase Ⅱ trail of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormonerefractory prostate cancer 显示文摘	Hudes GR Nathan F Khater C	1997	J Clin Oncol1997，15，9：	1
13	Randomized phase Ⅱ trial of sunitinib on an inter- mittent versus continuous dosing schedule as fimt-line therapy for advanced renal cell carcinoma 显示文摘	Motzer R J Hutson TE Olsen MR Hudes GR Burke JM Eden- field W J	2012	J Clin Oncol2012，30，12：	1
14	Preservation of immune effector cellfunction following administration of a dose intense 5-fluorouiacil chemotherapy regiman显示文摘	Weiner LM Hudes GR Kitson J	1993	CancerImmunol Immunither1993，36，3：	1
15	Targeting mTOR in renal cell carcinoma 显示文摘	Hudes GR	2009	Cancer2009，115，10：	1
16	Sequential axitinib (AG-013736) therapy of patients (pts) with metastatic clear cell renal cell cancer (RCC) refractory to sunitinib and sorafenib, cytokines and sorafenib, or sorafenib alone 显示文摘	Dutcher JP Wilding G Hudes GR	2008	J Clin Oncol2008，26，20：	1
17	Targeting mTOR in renal cell carcinama显示文摘	Hudes GR	2009	Caneer2009，115，10：	1
18	Targeting mTOR in renal cell carcinoma显示文摘	Hudes GR	2009	Cancer2009，115，：	1
19	Targeting mTOR in renal cell carcinoma显示文摘	Hudes GR	2009	Cancer2009，115，10：	1
20	Phase I pharmacokinetic trialof perillyl alcohol(NSC 641066)in patients with refractory solidmalignancies显示文摘	Hudes GR Szarka CE Adams A	2000	Clin Cancer Res2000，6，：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示